Patents by Inventor Jesper Worm

Jesper Worm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR
    Publication number: 20100234451
    Abstract: The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of the androgen receptor expression is beneficial for the treatment of certain disorders, such as a hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.
    Type: Application
    Filed: March 18, 2010
    Publication date: September 16, 2010
    Applicants: ENZON PHARMACEUTICALS, INC., SANTARIS PHARMA A/S
    Inventor: Jesper WORM
  • LNA antagonists targeting the androgen receptor
    Patent number: 7737125
    Abstract: The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of androgen receptor expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: June 15, 2010
    Assignees: Enzon Pharamaceuticals, Inc., Santaris Pharma, A/S
    Inventor: Jesper Worm
  • COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION
    Publication number: 20090203137
    Abstract: The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
    Type: Application
    Filed: January 21, 2009
    Publication date: August 13, 2009
    Applicant: Santaris Pharma A/S
    Inventor: Jesper Worm
  • LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR
    Publication number: 20090181916
    Abstract: The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of androgen receptor expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.
    Type: Application
    Filed: November 26, 2008
    Publication date: July 16, 2009
    Inventor: Jesper Worm
  • COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION
    Publication number: 20090005335
    Abstract: The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
    Type: Application
    Filed: April 30, 2008
    Publication date: January 1, 2009
    Applicant: Santaris Pharma A/S
    Inventor: Jesper Worm